3D printed tacrolimus tablet as well as preparation method and application thereof

Through 3D printing technology combined with mesoporous silica encapsulation and lipid materials, the problems of low solubility and specification limitations of tacrolimus are solved, and a 3D printing preparation with strong solubility and high stability is achieved, suitable for organs Treatment of rejection prevention after transplantation and multiple myositis.

CN119055643APending Publication Date: 2024-12-03ACADEMY OF MILITARY MEDICAL SCIENCES
View PDF 5 Cites 0 Cited by

Patent Information

Application Number
CN202411212057.8
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-30
Publication Date
2024-12-03

AI Technical Summary

Technical Problem

The low solubility and specification of tacrolimus have become a bottleneck in clinical application, especially in reducing the risk of rejection after organ transplantation and treating multiple myositis.

Method used

Using 3D printing technology to develop a semi-solid material containing a mesoporous silica-encapsulated tacrolimus solid dispersion, combined with lipid materials, fillers and plasticizers, and prepared by heating and stirring to form soluble Strong and stable 3D printing preparation.

Benefits of technology

The solubility of tacrolimus has been improved, and a 3D printed preparation with strong solubility, high stability and accurate dosage has been prepared. It is suitable for the treatment of clinically insoluble drugs, simplified the preparation process and is suitable for industrial production.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure SMS_1
    Figure SMS_1
  • Figure HDA0005020553800000011
    Figure HDA0005020553800000011
  • Figure HDA0005020553800000012
    Figure HDA0005020553800000012
Patent Text Reader

Abstract

The invention relates to a 3D (three-dimensional) printing tacrolimus semisolid material, which is prepared from the following components in percentage by weight: 0.1 to 10 percent of tacrolimus solid dispersion (tacrolise-SiO2SD) entrapped by mesoporous silica, 40 to 80 percent of lipid material, 5 to 35 percent of filler and 10 to 30 percent of plasticizer. The 3D printing tacrolimus semisolid material is used for 3D printing, a 3D printing preparation which is high in solubility, good in stability, high in safety and accurate in dosage is obtained, and a new solution is provided for clinical treatment of indissolvable drugs.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of medicine, and in particular to a 3D printed tacrolimus tablet, a preparation method thereof and an application thereof. Background Art

[0002] Tacrolimus is a macrolide immunosuppressant. Its main purpose is to reduce the activity of the patient's immune system after organ transplantation, thereby reducing the risk of organ rejection. It is a first-line drug for the treatment of kidney transplant rejection. Tacrolimus is available in two forms: topical ointment and oral preparations. Oral preparations are generally used for discomfort symptoms caused by diseases such as systemic lupus erythematosus and Sjögren's syndrome, anti-infection effects of some bacteria and viruses, polymyositis related to myasthenia gravis, and ulcerative colitis. However, this drug has a narrow therapeutic window and large individual differences. Clinical monitoring and strict control of drug dosage are required during treatment. At present, the specifications of tacrolimus preparations on the market are 5mg and 1mg. The specifications are limited, and the marketed drugs need to be divided into doses during clinical use. In addition, the saturated solubility of tacrolimus in water is only 1.24×10 -2 mg / L (25℃), and is almost insoluble in water. This low solubility characteristic limits the clinical application of tacrolimus.

[0003] 3D printing technology has the advantages of accurate dosage, arbitrary dosage, good patient compliance, saving manpower and material costs, and traceable operation specifications. Therefore, 3D printing technology can be used to develop a new dosage form of tacrolimus that can efficiently and conveniently control drug dosage. Summary of the invention

[0004] The object of the present invention is to provide a 3D printed tacrolimus semi-solid material, which contains, by weight percentage, 0.1-10% of a mesoporous silica-encapsulated tacrolimus solid dispersion (tacrolimus-SiO2 SD), 40-80% of a lipid material, 5-35% of a filler, and 10-30% of a plasticizer.

[0005] In the preferred technical solution of the present invention, the composition contains 0.2-5% tacrolimus-SiO2SD by weight, preferably 0.3-1%.

[0006] In a preferred technical solution of the present invention, the lipid material is selected from any one or a combination of polyethylene glycol-32-stearate, phospholipids, cholesterol and fat emulsion.

[0007] In a preferred technical solution of the present invention, the composition contains 45-75% lipid material by weight, preferably 50-70%.

[0008] In a preferred technical solution of the present invention, the filler is selected from any one of mannitol, starch, microcrystalline cellulose, lactose, and dextrin, or a combination thereof.

[0009] In a preferred technical solution of the present invention, the composition contains 8-32% filler, preferably 10-30% filler, by weight percentage.

[0010] In a preferred technical solution of the present invention, the plasticizer is selected from any one of glycerol, polyethylene glycol (PEG), dibutyl phthalate, dioctyl adipate, dibutyl sebacate and sorbitol, or a combination thereof.

[0011] In a preferred technical solution of the present invention, the composition contains 12-28% plasticizer by weight, preferably 15-25%.

[0012] In the preferred technical solution of the present invention, the composition contains, by weight percentage, 0.2-5% of tacrolimus-SiO2 SD, 45-75% of lipid material, 8-32% of filler, and 12-28% of plasticizer.

[0013] In the preferred technical solution of the present invention, the composition contains, by weight percentage, 0.3-1% of tacrolimus-SiO2 SD, 50-70% of lipid material, 10-30% of filler, and 15-25% of plasticizer.

[0014] In a preferred technical solution of the present invention, the content of tacrolimus in the tacrolimus-SiO2 SD is 5-30%, preferably 10-25%.

[0015] In the preferred technical scheme of the present invention, the preparation method of the 3D printed tacrolimus semi-solid material comprises the following steps: heating the required amount of lipid material at 60-80°C until completely melted, adding the required amount of filler, plasticizer and tacrolimus-SiO2 SD, and stirring evenly at 30-60°C to obtain.

[0016] In the preferred technical solution of the present invention, the stirring speed is 50-300 rpm, preferably 70-200 rpm.

[0017] In the preferred technical scheme of the present invention, the preparation process of the mesoporous silica-encapsulated tacrolimus solid dispersion is as follows: a tacrolimus acetone solution with a concentration of 20-50 mg / mL is added dropwise to the mesoporous silica heated to 70-80°C, stirred and mixed, and then dried at 50-60°C to obtain the solid dispersion.

[0018] In the preferred technical solution of the present invention, the dropping speed is 0.01-0.10 mL / min.

[0019] In the preferred technical solution of the present invention, the stirring speed is 50-300 rpm, preferably 70-200 rpm.

[0020] The object of the present invention is to provide a method for preparing a 3D printed tacrolimus semi-solid material, which contains, by weight percentage, 0.1-10% of a mesoporous silica-encapsulated tacrolimus solid dispersion (tacrolimus-SiO2 SD), 40-80% of a lipid material, 5-35% of a filler, and 10-30% of a plasticizer. The method for preparing the 3D printed tacrolimus semi-solid material comprises the following steps: heating a required amount of lipid material at 60-80° C. until completely melted, adding a required amount of filler, plasticizer and tacrolimus-SiO2 SD, and stirring evenly at 30-60° C. to obtain the product.

[0021] In the preferred technical solution of the present invention, the stirring speed is 50-300 rpm, preferably 70-200 rpm.

[0022] In the preferred technical scheme of the present invention, the preparation process of the mesoporous silica-encapsulated tacrolimus solid dispersion is: 20-50 mg / mL tacrolimus acetone solution is added dropwise to the mesoporous silica heated to 70-80°C, stirred and mixed, and then dried at 50-60°C to obtain the solid dispersion.

[0023] In the preferred technical solution of the present invention, the dropping speed is 0.01-0.10 mL / min.

[0024] In the preferred technical solution of the present invention, the stirring speed is 50-300 rpm, preferably 70-200 rpm.

[0025] In the preferred technical solution of the present invention, the composition contains 0.2-5% tacrolimus-SiO2SD by weight, preferably 0.3-1%.

[0026] In a preferred technical solution of the present invention, the lipid material is selected from any one or a combination of polyethylene glycol-32-stearate, phospholipids, cholesterol and fat emulsion.

[0027] In a preferred technical solution of the present invention, the composition contains 45-75% lipid material by weight, preferably 50-70%.

[0028] In a preferred technical solution of the present invention, the filler is selected from any one of mannitol, starch, microcrystalline cellulose, lactose, and dextrin, or a combination thereof.

[0029] In a preferred technical solution of the present invention, the composition contains 8-32% filler, preferably 10-30% filler, by weight percentage.

[0030] In a preferred technical solution of the present invention, the plasticizer is selected from any one of glycerol, polyethylene glycol (PEG), dibutyl phthalate, dioctyl adipate, dibutyl sebacate and sorbitol, or a combination thereof.

[0031] In a preferred technical solution of the present invention, the composition contains 12-28% plasticizer by weight, preferably 15-25%.

[0032] In the preferred technical solution of the present invention, the composition contains, by weight percentage, 0.2-5% of tacrolimus-SiO2 SD, 45-75% of lipid material, 8-32% of filler, and 12-28% of plasticizer.

[0033] In the preferred technical solution of the present invention, the composition contains, by weight percentage, 0.3-1% of tacrolimus-SiO2 SD, 50-70% of lipid material, 10-30% of filler, and 15-25% of plasticizer.

[0034] In a preferred technical solution of the present invention, the content of tacrolimus in the tacrolimus-SiO2 SD is 5-30%, preferably 10-25%.

[0035] Another object of the present invention is to provide a method for preparing a 3D printed tacrolimus preparation, comprising the following steps: loading the 3D printed tacrolimus semi-solid material of the present invention into a 3D printer barrel, setting printing parameters, and performing 3D printing to obtain.

[0036] In the preferred technical solution of the present invention, preheating at the printing temperature is 20-50 minutes, preferably 30-40 minutes.

[0037] In the preferred technical solution of the present invention, the printing temperature is 30-100°C, preferably 30-80°C, and more preferably 40-50°C.

[0038] In the preferred technical solution of the present invention, the printing layer height is 0.1-1.2 mm, preferably 0.2-0.8 mm, and more preferably 0.3-0.6 mm.

[0039] In the preferred technical solution of the present invention, the printing rate is 5-40 mm / s, preferably 10-35 mm / s, and more preferably 20-30 mm / s.

[0040] In the preferred technical solution of the present invention, the filling method is selected from any one of grid filling, concentric circle filling, honeycomb filling or a combination thereof.

[0041] In a preferred technical solution of the present invention, the filling rate of the 3D printing agent is 5-100%, preferably 10-80%, and more preferably 15-30%.

[0042] In the preferred technical solution of the present invention, the shape of the 3D printed preparation is selected from any one of a circular shape, annular shape, square shape, diamond shape, pea shape, capsule shape, cloud shape, petal shape, heart shape, bear shape or a combination thereof.

[0043] Another object of the present invention is to provide a 3D printed tacrolimus preparation prepared by the preparation method of the 3D printed tacrolimus preparation described in the present invention.

[0044] Another object of the present invention is to provide a 3D printed tacrolimus preparation for use in the preparation of immunosuppressant drugs.

[0045] In the preferred technical scheme of the present invention, the drug includes any one or a combination of drugs for treating discomfort symptoms caused by diseases such as systemic lupus erythematosus, Sjögren's syndrome, the anti-infection effect of some bacteria and viruses, polymyositis related to myasthenia gravis, and ulcerative colitis, or their complications.

[0046] In a preferred technical solution of the present invention, the treated patient is selected from any one of infant patients, child patients, adult patients, elderly patients, and seriously ill patients.

[0047] In a preferred technical solution of the present invention, the preparation also includes a second therapeutic drug.

[0048] Unless otherwise specified, when the present invention relates to the percentage between liquids, the percentage is volume / volume percentage; when the present invention relates to the percentage between liquids and solids, the percentage is volume / weight percentage; when the present invention relates to the percentage between solids and liquids, the percentage is weight / volume percentage; the rest are weight / weight percentages.

[0049] Unless otherwise stated, the present invention uses the following method for detection:

[0050] 1. Disintegration time: Hang the hanging basket on the bracket through the stainless steel shaft at the upper end, immerse it in a 1000mL beaker, and adjust the position of the hanging basket so that when it drops to the lowest point, the screen is 25mm away from the bottom of the beaker. The beaker is filled with water at a temperature of 37℃±1℃. Adjust the water level so that when the hanging basket rises to the highest point, the screen is 15mm below the water surface. The top of the hanging basket cannot be immersed in the solution. Take the test sample and place it in the glass tube of the above hanging basket respectively, start the disintegration instrument for inspection, and record the complete disintegration time.

[0051] 2. Differential Scanning Calorimetry (DSC): Using a blank aluminum crucible as a reference, about 10 mg of sample was placed in the test crucible, and differential thermal analysis was performed on tacrolimus API, mesoporous silica, tacrolimus / mesoporous silica physical mixture, and different concentrations of tacrolimus-SiO2 SD. Test conditions: N2 atmosphere, heating rate 10℃ / min, scanning range 30-200℃.

[0052] 3. X-ray diffraction detection (XRD): X-ray diffraction measurements were performed on tacrolimus API, mesoporous silica, tacrolimus / mesoporous silica physical mixture and tacrolimus-SiO2SD with different concentrations. Test conditions: The powder sample was placed on a glass slide and tested using an X-ray diffractometer. The instrument model was Japan Ri gaku Smart Lab SE, the test range was 5-90°, the scanning speed was 2° / min, the light source was Cu-Kα rays, the tube voltage was 40kV, and the current was 40mA.

[0053] 4. The tacrolimus content in the 3D printed tacrolimus tablets was tested with reference to the USP-NF 2023 edition of the Pharmacopoeia.

[0054] Compared with the prior art, the present invention has the following beneficial effects:

[0055] 1. The 3D printed preparation of the present invention encapsulates tacrolimus by mesoporous silica to enhance the solubility of tacrolimus, and scientifically selects lipid materials, plasticizers, etc. as 3D printing materials, so as to obtain a 3D printed preparation with strong solubility, good stability, high safety and accurate dosage, which provides a new solution for clinical treatment of poorly soluble drugs.

[0056] 2. The preparation process of the 3D printing preparation of the present invention is simple and can be applied to industrial production. BRIEF DESCRIPTION OF THE DRAWINGS

[0057] Figure 1 Scanning electron microscope image of tacrolimus-SiO2 SD of the present invention;

[0058] Figure 2 In vitro dissolution study of tacrolimus-Si O2 SD of the present invention;

[0059] Figure 3 Study on the DSC results of the 3D printed tacrolimus preparation of the present invention;

[0060] Figure 4 Study on XRD results of 3D printed tacrolimus preparations of the present invention;

[0061] Figure 5 Study on the dissolution results of the 3D printed tacrolimus preparation of the present invention. DETAILED DESCRIPTION

[0062] The present invention will be specifically described below in conjunction with embodiments. The embodiments of the present invention are only used to illustrate the technical solutions of the present invention and are not intended to limit the essence of the present invention.

[0063] Tacrolimus API (Jiangsu Joyoung Biotechnology Co., Ltd.); mesoporous silica (Merck); hydroxypropyl cellulose (Ash l and); acetonitrile (Thermo Fisher Scientific, USA); acetone (Sinopharm Chemical Reagent Co., Ltd.); phosphoric acid (Beijing Sinopharm Chemical Reagent Co., Ltd.); and deionized water.

[0064] Magnetic stirrer (SCILOGEX MS-H280-Pro); microfluidic syringe pump (CHEMYX Fusion4000); vacuum drying oven (DZF-6020, Shanghai Hengyi Scientific Instrument Co., Ltd.); dissolution apparatus (RC806D, Tianjin Tianda Tianfa Technology Co., Ltd.); constant temperature oscillator (HNY-200D, Tianjin Ounuo Instrument Co., Ltd.); high performance liquid chromatograph (Thermo Ultramate3000); scanning electron microscope (ZEISS Gemini 300); fully automatic specific surface area and pore analyzer BET (Micromeritics 3FLEX, USA); differential scanning calorimeter (TAQ2000); X-ray diffractometer (Smart Lab-SE, Rigaku, Japan).

[0065] Example 1 Preparation of Tacrolimus-SiO2 SD of the Present Invention

[0066] (1) Weigh 0.45 mg of mesoporous silica into a beaker and add a magnet of appropriate size. Place the beaker on a constant temperature magnetic stirrer and heat to 55°C.

[0067] (2) Dissolve 0.3 g of tacrolimus in 10 mL of acetone to prepare a 30 mg / mL tacrolimus acetone solution. Aspirate the solution into a 10 mL syringe. Fix the syringe on a microfluidic syringe pump and place it above a beaker. Add 5 mL of the solution dropwise to the beaker at a dropping speed of 0.08 mL / min and a stirring speed of 150 rpm. Dry at 40 °C for 6 h and pass through a 100 mesh sieve to obtain tacrolimus-SiO2 SD.

[0068] The morphology of tacrolimus API, tacrolimus-SiO2SD and mesoporous silica was characterized by scanning electron microscopy (SEM). Figure 1 As shown (tacrolimus API ( Figure 1 A), Tacrolimus-SiO2 SD ( Figure 1 B), mesoporous silica ( Figure 1C)). The particle size analyzer detected that the D 50 The particle sizes were 25.62 μm and 27.29 μm respectively, and there was no obvious change in particle size.

[0069] Using 0.005% HPC (hydroxypropyl cellulose) solution with a pH of 4.5 as the dissolution medium, 0.6 g of tacrolimus-SiO2 SD (n=3), 0.15 g of tacrolimus (n=3), and a physical mixture of 0.15 g of tacrolimus and 0.45 g of mesoporous silica (n=3) were added to 500 mL of the dissolution medium, respectively. The dissolution medium was placed in a conical flask and shaken at 37°C and 100 rpm. Samples were taken at 15 min, 30 min, 45 min, 60 min, 90 min, and 120 min for HPLC detection. The results were as follows: Figure 2 shown.

[0070] Example 2 Preparation of 3D printing semi-solid material of the present invention

[0071] Composition of the 3D printing semi-solid material of the present invention:

[0072] Components Dosage(g) <![CDATA[Tacrolimus-SiO2 SD of Example 1]]> 0.4 Polyethylene glycol PEG 400 19.6 Microcrystalline Cellulose MCC 102 20 Macrogol-32-stearate Gel 48 / 16 60

[0073] The preparation of the 3D printing semi-solid material of the present invention comprises the following steps:

[0074] Heat the required amount of Gel 48 / 16 at 60°C until it is completely melted, add the required amount of microcrystalline cellulose 102, PEG 400 and tacrolimus-SiO2 SD of Example 1, and stir evenly at 60°C and 100 rpm to obtain the product.

[0075] Example 3 Preparation of 3D printing semi-solid material of the present invention

[0076] Composition of the 3D printing semi-solid material of the present invention:

[0077] Components Dosage(g) <![CDATA[Tacrolimus-SiO2 SD of Example 1]]> 0.4 Polyethylene glycol PEG 400 19.6 Microcrystalline Cellulose MCC 105 20 Macrogol-32-stearate Gel 48 / 16 60

[0078] The preparation of the 3D printing semi-solid material of the present invention comprises the following steps:

[0079] Heat the required amount of Gel 48 / 16 at 60°C until it is completely melted, then add the required amounts of microcrystalline cellulose 105, PEG 400 and tacrolimus-SiO2 SD of Example 1, and stir evenly at 60°C and 80 rpm to obtain the product.

[0080] Example 4 Preparation of 3D Printing Semi-solid Material of the Present Invention

[0081] Composition of the 3D printing semi-solid material of the present invention:

[0082] Components Dosage(g) <![CDATA[Tacrolimus-SiO2 SD of Example 1]]> 0.4 Polyethylene glycol PEG 400 19.6 Microcrystalline Cellulose MCC 105 25 Macrogol-32-stearate Gel 48 / 16 55

[0083] The preparation of the 3D printing semi-solid material of the present invention comprises the following steps:

[0084] Heat the required amount of Gel 48 / 16 at 60°C until it is completely melted, add the required amount of microcrystalline cellulose 105, PEG 400 and tacrolimus-SiO2 SD of Example 1, and stir evenly at 60°C and 120 rpm to obtain the product.

[0085] Example 5 Preparation of 3D printing semi-solid material of the present invention

[0086] Composition of the 3D printing semi-solid material of the present invention:

[0087] Components Dosage(g) <![CDATA[Tacrolimus-SiO2 SD of Example 1]]> 0.4 Polyethylene glycol PEG 400 19.6 Microcrystalline Cellulose MCC 105 10 Macrogol-32-stearate Gel 48 / 16 70

[0088] The preparation of the 3D printing semi-solid material of the present invention comprises the following steps:

[0089] Heat the required amount of Gel 48 / 16 at 60°C until it is completely melted, add the required amounts of microcrystalline cellulose 105, PEG 400 and tacrolimus-SiO2SD of Example 1, and stir evenly at 60°C and 70 rpm to obtain the mixture.

[0090] Example 6 Preparation of 3D Printing Semi-solid Material of the Present Invention

[0091] Composition of the 3D printing semi-solid material of the present invention:

[0092] Components Dosage(g) <![CDATA[Tacrolimus-SiO2 SD of Example 1]]> 0.4 Polyethylene glycol PEG 400 19.6 Microcrystalline Cellulose MCC 105 30 Macrogol-32-stearate Gel 48 / 16 50

[0093] The preparation of the 3D printing semi-solid material of the present invention comprises the following steps:

[0094] Heat the required amount of Gel 48 / 16 at 60°C until it is completely melted, add the required amounts of microcrystalline cellulose 105, PEG 400 and tacrolimus-SiO2SD of Example 1, and stir evenly at 60°C and 130 rpm to obtain the product.

[0095] Example 7 Preparation of 3D printed tacrolimus tablets of the present invention

[0096] A disposable syringe filled with the 3D printed semi-solid material of Example 2 was placed in the printer barrel and preheated at the printing temperature for about 30 minutes. The model of the cylinder was designed using Rhino 6.5 software, and the model was exported in .stl format and imported into the Printer Host V 2.2.2 printing software. The printing parameters were set and sliced: the printing temperature was 42.0°C, the initial layer height was 0.6 mm, the layer height was 0.5 mm, the printing speed was 20 mm / s, the filling amount was 15%, and 0.5 mg of 3D printed tacrolimus tablets were printed.

[0097] Example 8 Preparation of 3D printed tacrolimus tablets of the present invention

[0098] A disposable syringe containing the 3D printed semi-solid material of Example 3 was placed in the barrel of a 3D printer and preheated at the printing temperature for about 30 min. The model of the cylinder was designed using Rhino 6.5 software, and the model was exported in .stl format and imported into the Printer Host V 2.2.2 printing software. The printing parameters were set and sliced: the printing temperature was 42.0°C, the initial layer height was 0.6 mm, the layer height was 0.5 mm, the printing speed was 20 mm / s, the filling amount was 15%, and 1.0 mg of 3D printed tacrolimus tablets were printed.

[0099] Example 9 Preparation of 3D printed tacrolimus tablets of the present invention

[0100] A disposable syringe containing the 3D printed semi-solid material of Example 4 was placed in the barrel of a 3D printer and preheated at the printing temperature for about 30 min. The model of the cylinder was designed using Rhino 6.5 software, and the model was exported in .stl format and imported into the Printer Host V 2.2.2 printing software. The printing parameters were set and sliced: the printing temperature was 42.0°C, the initial layer height was 0.6 mm, the layer height was 0.5 mm, the printing speed was 20 mm / s, the filling amount was 15%, and 2.0 mg of 3D printed tacrolimus tablets were printed.

[0101] Example 10 Preparation of 3D printed tacrolimus tablets of the present invention

[0102] A disposable syringe containing the 3D printed semi-solid material of Example 5 was placed in the barrel of a 3D printer and preheated at the printing temperature for about 30 minutes. The model of the cylinder was designed using Rhino 6.5 software, and the model was exported in .stl format and imported into the Printer Host V 2.2.2 printing software. The printing parameters were set and sliced: the printing temperature was 42.0°C, the initial layer height was 0.6 mm, the layer height was 0.5 mm, the printing speed was 20 mm / s, the filling amount was 15%, and 4.0 mg of 3D printed tacrolimus tablets were printed.

[0103] Example 11 Preparation of 3D printed tacrolimus tablets of the present invention

[0104] A disposable syringe containing the 3D printed semi-solid material of Example 6 was placed in the barrel of a 3D printer and preheated at the printing temperature for about 30 min. The model of the cylinder was designed using Rhino 6.5 software, and the model was exported in .stl format and imported into the Printer Host V 2.2.2 printing software. The printing parameters were set and sliced: the printing temperature was 42.0°C, the initial layer height was 0.6 mm, the layer height was 0.5 mm, the printing speed was 20 mm / s, the filling amount was 15%, and 4.0 mg of 3D printed tacrolimus tablets were printed.

[0105] Experimental Example 1 Performance Characterization of 3D Printed Tacrolimus Tablets of the Present Invention

[0106] According to the detection method of the present invention, the tablet weight, disintegration time and hardness of the 3D printed tacrolimus tablets of Examples 7-11 were detected, as shown in Table 1.

[0107] Table 1

[0108]

[0109] Experimental Example 2 In vitro release study of the 3D printed tacrolimus tablets of the present invention

[0110] According to the detection method of the present invention, DSC and XRD of Examples 7-10, physical mixture, blank auxiliary material and tacrolimus were detected. The results are shown in Figure 3-4 The physical mixture is a physical mixture of 0.15g tacrolimus and 0.45g mesoporous silica; the blank auxiliary material is 50g of Gel 48 / 16 heated at 60°C to completely melt, then 30g of microcrystalline cellulose 105 and 20g of PEG 400 are added, and stirred evenly at 60°C and 130rpm to obtain the blank auxiliary material.

[0111] Experimental Example 3 In vitro release study of the 3D printed tacrolimus tablets of the present invention

[0112] The 3D printed tacrolimus tablets of Examples 7-10 (n=3) were subjected to in vitro dissolution test. Dissolution method: 0.005% HPC solution with a pH of 4.5 was used as the dissolution medium, and the mixture was shaken at 37°C and 100 rpm for 2 h. Samples were taken at 15 min, 30 min, 45 min, 60 min, 90 min and 120 min to detect the release. The dissolution curve is shown in Figure 2. Figure 4 As shown, it meets the requirements of pharmacopoeia.

[0113] Experimental Example 4 Study on the long-term stability of the 3D printed tacrolimus tablets of the present invention

[0114] The 1 mg 3D printed tacrolimus tablets of Example 8 were sealed and packaged in PET / AL / PE plain foil bags. Stability studies were conducted at 25°C and a humidity of 60.0%±5.0%. Samples were taken at 0 days, 1 month, 2 months, and 3 months to test the tablet properties, content, and dissolution. The results are shown in Table 2.

[0115] Table 2

[0116] Inspection time shape content(%) 90min dissolution rate (%) Day 0 White round tablets 100.48 94.67 1 month No abnormality found 101.09 94.72 2 months No abnormality found 98.92 97.51 3 months No abnormality found 97.92 97.69

[0117] The above description of the specific embodiments of the present invention does not limit the present invention. Those skilled in the art may make various changes or modifications based on the present invention. As long as they do not depart from the spirit of the present invention, they should all fall within the scope of protection of the claims of the present invention.

Claims

1. A 3D printed tacrolimus semi-solid material, comprising, by weight percentage, 0.1-10% of a mesoporous silica-encapsulated tacrolimus solid dispersion (tacrolimus-SiO2 SD), 40-80% of a lipid material, 5-35% of a filler, and 10-30% of a plasticizer.

2. The 3D printed tacrolimus semi-solid material according to claim 1, wherein the lipid material is selected from any one of polyethylene glycol-32-stearate, phospholipids, cholesterol and fat emulsion or a combination thereof.

3. The 3D printed tacrolimus semisolid material according to any one of claims 1 to 2, wherein the filler is selected from any one of mannitol, starch, microcrystalline cellulose, lactose, dextrin, or a combination thereof.

4. The 3D printed tacrolimus semi-solid material according to any one of claims 1 to 3, wherein the plasticizer is selected from any one or a combination of glycerol, polyethylene glycol, dibutyl phthalate, dioctyl adipate, dibutyl sebacate and sorbitol.

5. The 3D printed tacrolimus semi-solid material according to any one of claims 1 to 4, wherein the preparation method of the 3D printed tacrolimus semi-solid material comprises the following steps: heating the required amount of lipid material at 60-80° C. until completely melted, adding the required amount of filler, plasticizer and tacrolimus-SiO2 SD, and stirring evenly at 30-60° C. to obtain.

6. The 3D printed tacrolimus semi-solid material according to any one of claims 1 to 5, wherein the preparation process of the tacrolimus-SiO2 SD is as follows: 20-50 mg / mL of tacrolimus acetone solution is added dropwise to mesoporous silica heated to 70-80°C, stirred and mixed, and then dried at 50-60°C to obtain the tacrolimus semi-solid material.

7. A method for preparing a 3D printed tacrolimus semi-solid material as described in any one of claims 1 to 6, comprising the following steps: heating a required amount of lipid material at 60-80° C. until completely melted, adding a required amount of filler, plasticizer and tacrolimus-SiO2SD, and stirring evenly at 30-60° C. to obtain.

8. A method for preparing a 3D printed tacrolimus preparation, specifically comprising: loading the 3D printed tacrolimus semi-solid material according to any one of claims 1 to 6 into a 3D printer barrel, setting printing parameters, and performing 3D printing to obtain the product.

9. The 3D printed tacrolimus preparation prepared by the method for preparing the 3D printed tacrolimus preparation according to claim 8.

10. Use of the 3D printed tacrolimus preparation according to claim 9 in the preparation of immunosuppressant drugs.

Citation Information

Patent Citations

  • Tacrolimus solid dispersion

    CN103479600A

  • Tacrolimus sustained-release tablets and preparation method thereof

    CN106309395A

  • 3D printing preparation as well as preparation method and application thereof

    CN113599362A

  • 3D printing preparation as well as preparation method and application thereof

    CN115414332A

  • Tacrolimus sustained-release pharmaceutical composition and preparation method thereof

    CN115624525A